nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—EPHA3—cleft lip	0.713	1	CbGaD
Crizotinib—LTK—tongue—cleft lip	0.00283	0.0337	CbGeAlD
Crizotinib—SRC—periosteum—cleft lip	0.00273	0.0326	CbGeAlD
Crizotinib—CSF1R—periosteum—cleft lip	0.00245	0.0292	CbGeAlD
Crizotinib—LTK—mouth—cleft lip	0.0019	0.0226	CbGeAlD
Crizotinib—ANKK1—telencephalon—cleft lip	0.00184	0.0219	CbGeAlD
Crizotinib—MET—mouth—cleft lip	0.00172	0.0205	CbGeAlD
Crizotinib—EPHA4—tongue—cleft lip	0.00156	0.0185	CbGeAlD
Crizotinib—PRKD3—embryo—cleft lip	0.00142	0.0169	CbGeAlD
Crizotinib—MET—embryo—cleft lip	0.00123	0.0146	CbGeAlD
Crizotinib—LIMK2—mouth—cleft lip	0.00121	0.0144	CbGeAlD
Crizotinib—PRKD1—telencephalon—cleft lip	0.0012	0.0143	CbGeAlD
Crizotinib—LIMK1—telencephalon—cleft lip	0.00119	0.0141	CbGeAlD
Crizotinib—PRKD3—telencephalon—cleft lip	0.00115	0.0138	CbGeAlD
Crizotinib—ANKK1—head—cleft lip	0.00115	0.0136	CbGeAlD
Crizotinib—ACVR1B—embryo—cleft lip	0.00114	0.0135	CbGeAlD
Crizotinib—DSTYK—telencephalon—cleft lip	0.00113	0.0134	CbGeAlD
Crizotinib—CASK—telencephalon—cleft lip	0.0011	0.0131	CbGeAlD
Crizotinib—DCLK1—embryo—cleft lip	0.00108	0.0128	CbGeAlD
Crizotinib—MAPK7—telencephalon—cleft lip	0.00107	0.0127	CbGeAlD
Crizotinib—EPHA4—mouth—cleft lip	0.00105	0.0125	CbGeAlD
Crizotinib—PTK2—mouth—cleft lip	0.001	0.012	CbGeAlD
Crizotinib—ALK—embryo—cleft lip	0.001	0.012	CbGeAlD
Crizotinib—MET—telencephalon—cleft lip	0.000999	0.0119	CbGeAlD
Crizotinib—IGF1R—embryo—cleft lip	0.000965	0.0115	CbGeAlD
Crizotinib—ACVR1B—telencephalon—cleft lip	0.000923	0.011	CbGeAlD
Crizotinib—DCLK1—telencephalon—cleft lip	0.000875	0.0104	CbGeAlD
Crizotinib—NEK9—head—cleft lip	0.000821	0.00977	CbGeAlD
Crizotinib—EPHA5—telencephalon—cleft lip	0.000817	0.00973	CbGeAlD
Crizotinib—TYRO3—telencephalon—cleft lip	0.000817	0.00973	CbGeAlD
Crizotinib—TNK2—telencephalon—cleft lip	0.000785	0.00935	CbGeAlD
Crizotinib—IGF1R—telencephalon—cleft lip	0.000785	0.00935	CbGeAlD
Crizotinib—PTK2B—embryo—cleft lip	0.000778	0.00927	CbGeAlD
Crizotinib—PRKD1—head—cleft lip	0.000748	0.00891	CbGeAlD
Crizotinib—EPHA4—embryo—cleft lip	0.000746	0.00888	CbGeAlD
Crizotinib—SIK2—head—cleft lip	0.000738	0.00879	CbGeAlD
Crizotinib—MERTK—telencephalon—cleft lip	0.000718	0.00855	CbGeAlD
Crizotinib—PTK2—embryo—cleft lip	0.000716	0.00853	CbGeAlD
Crizotinib—MAP3K12—telencephalon—cleft lip	0.000695	0.00827	CbGeAlD
Crizotinib—ACVR1—telencephalon—cleft lip	0.000695	0.00827	CbGeAlD
Crizotinib—RPS6KB1—embryo—cleft lip	0.000689	0.00821	CbGeAlD
Crizotinib—LTK—head—cleft lip	0.000686	0.00817	CbGeAlD
Crizotinib—FGR—embryo—cleft lip	0.000685	0.00816	CbGeAlD
Crizotinib—MAPK7—head—cleft lip	0.000664	0.00791	CbGeAlD
Crizotinib—TXK—head—cleft lip	0.000664	0.00791	CbGeAlD
Crizotinib—EPHA8—head—cleft lip	0.000658	0.00783	CbGeAlD
Crizotinib—JAK2—embryo—cleft lip	0.000647	0.00771	CbGeAlD
Crizotinib—PTK2B—telencephalon—cleft lip	0.000633	0.00754	CbGeAlD
Crizotinib—TEK—embryo—cleft lip	0.000624	0.00743	CbGeAlD
Crizotinib—MET—head—cleft lip	0.000622	0.00741	CbGeAlD
Crizotinib—EPHA4—telencephalon—cleft lip	0.000607	0.00723	CbGeAlD
Crizotinib—CDK7—head—cleft lip	0.000602	0.00716	CbGeAlD
Crizotinib—MAP3K2—telencephalon—cleft lip	0.000595	0.00709	CbGeAlD
Crizotinib—PTK2—telencephalon—cleft lip	0.000583	0.00694	CbGeAlD
Crizotinib—TBK1—telencephalon—cleft lip	0.000583	0.00694	CbGeAlD
Crizotinib—TYK2—telencephalon—cleft lip	0.000579	0.00689	CbGeAlD
Crizotinib—ACVR1B—head—cleft lip	0.000575	0.00685	CbGeAlD
Crizotinib—EPHA3—head—cleft lip	0.000575	0.00685	CbGeAlD
Crizotinib—IRAK1—telencephalon—cleft lip	0.000571	0.0068	CbGeAlD
Crizotinib—RPS6KB1—telencephalon—cleft lip	0.00056	0.00668	CbGeAlD
Crizotinib—AXL—telencephalon—cleft lip	0.000555	0.00661	CbGeAlD
Crizotinib—SRC—embryo—cleft lip	0.000554	0.0066	CbGeAlD
Crizotinib—EPHA6—head—cleft lip	0.000548	0.00653	CbGeAlD
Crizotinib—JAK3—head—cleft lip	0.000548	0.00653	CbGeAlD
Crizotinib—DCLK1—head—cleft lip	0.000545	0.00649	CbGeAlD
Crizotinib—STK4—head—cleft lip	0.000538	0.00641	CbGeAlD
Crizotinib—SLK—telencephalon—cleft lip	0.000534	0.00636	CbGeAlD
Crizotinib—EPHB4—telencephalon—cleft lip	0.00053	0.00632	CbGeAlD
Crizotinib—JAK2—telencephalon—cleft lip	0.000527	0.00627	CbGeAlD
Crizotinib—EPHA5—head—cleft lip	0.000509	0.00606	CbGeAlD
Crizotinib—ALK—head—cleft lip	0.000509	0.00606	CbGeAlD
Crizotinib—FER—head—cleft lip	0.000509	0.00606	CbGeAlD
Crizotinib—TYRO3—head—cleft lip	0.000509	0.00606	CbGeAlD
Crizotinib—MAP4K5—telencephalon—cleft lip	0.000507	0.00604	CbGeAlD
Crizotinib—TEK—telencephalon—cleft lip	0.000507	0.00604	CbGeAlD
Crizotinib—LYN—head—cleft lip	0.000506	0.00603	CbGeAlD
Crizotinib—BMPR1B—head—cleft lip	0.000498	0.00594	CbGeAlD
Crizotinib—MAP3K19—head—cleft lip	0.000498	0.00594	CbGeAlD
Crizotinib—CSF1R—embryo—cleft lip	0.000498	0.00593	CbGeAlD
Crizotinib—IGF1R—head—cleft lip	0.000489	0.00582	CbGeAlD
Crizotinib—TNK2—head—cleft lip	0.000489	0.00582	CbGeAlD
Crizotinib—EPHB6—telencephalon—cleft lip	0.000485	0.00578	CbGeAlD
Crizotinib—STK3—head—cleft lip	0.000476	0.00566	CbGeAlD
Crizotinib—TIE1—head—cleft lip	0.000476	0.00566	CbGeAlD
Crizotinib—YES1—telencephalon—cleft lip	0.000469	0.00558	CbGeAlD
Crizotinib—AURKA—head—cleft lip	0.000463	0.00552	CbGeAlD
Crizotinib—TAOK3—telencephalon—cleft lip	0.000463	0.00551	CbGeAlD
Crizotinib—TESK1—head—cleft lip	0.00046	0.00547	CbGeAlD
Crizotinib—SRC—telencephalon—cleft lip	0.000451	0.00537	CbGeAlD
Crizotinib—MERTK—head—cleft lip	0.000447	0.00533	CbGeAlD
Crizotinib—LIMK2—head—cleft lip	0.000437	0.00521	CbGeAlD
Crizotinib—MAP3K12—head—cleft lip	0.000433	0.00515	CbGeAlD
Crizotinib—ACVR1—head—cleft lip	0.000433	0.00515	CbGeAlD
Crizotinib—STK35—head—cleft lip	0.000424	0.00505	CbGeAlD
Crizotinib—BMP2K—head—cleft lip	0.000408	0.00486	CbGeAlD
Crizotinib—CSF1R—telencephalon—cleft lip	0.000405	0.00482	CbGeAlD
Crizotinib—PTK2B—head—cleft lip	0.000394	0.00469	CbGeAlD
Crizotinib—ABL1—embryo—cleft lip	0.000393	0.00469	CbGeAlD
Crizotinib—RIPK2—head—cleft lip	0.000391	0.00465	CbGeAlD
Crizotinib—EPHA4—head—cleft lip	0.000378	0.0045	CbGeAlD
Crizotinib—MAP3K2—head—cleft lip	0.00037	0.00441	CbGeAlD
Crizotinib—PTK2—head—cleft lip	0.000363	0.00432	CbGeAlD
Crizotinib—TBK1—head—cleft lip	0.000363	0.00432	CbGeAlD
Crizotinib—TYK2—head—cleft lip	0.00036	0.00429	CbGeAlD
Crizotinib—RPS6KB1—head—cleft lip	0.000349	0.00416	CbGeAlD
Crizotinib—FGR—head—cleft lip	0.000347	0.00413	CbGeAlD
Crizotinib—AXL—head—cleft lip	0.000345	0.00412	CbGeAlD
Crizotinib—JAK2—head—cleft lip	0.000328	0.00391	CbGeAlD
Crizotinib—EPHA2—head—cleft lip	0.000324	0.00386	CbGeAlD
Crizotinib—ABL1—telencephalon—cleft lip	0.00032	0.00381	CbGeAlD
Crizotinib—MAP4K5—head—cleft lip	0.000316	0.00376	CbGeAlD
Crizotinib—TEK—head—cleft lip	0.000316	0.00376	CbGeAlD
Crizotinib—MAP3K3—head—cleft lip	0.000316	0.00376	CbGeAlD
Crizotinib—EPHB6—head—cleft lip	0.000302	0.0036	CbGeAlD
Crizotinib—YES1—head—cleft lip	0.000292	0.00348	CbGeAlD
Crizotinib—STK10—head—cleft lip	0.000289	0.00344	CbGeAlD
Crizotinib—TAOK3—head—cleft lip	0.000288	0.00343	CbGeAlD
Crizotinib—SRC—head—cleft lip	0.000281	0.00334	CbGeAlD
Crizotinib—CSF1R—head—cleft lip	0.000252	0.003	CbGeAlD
Crizotinib—ABL1—head—cleft lip	0.000199	0.00237	CbGeAlD
Crizotinib—ABCB1—embryo—cleft lip	0.000122	0.00146	CbGeAlD
Crizotinib—ABCB1—telencephalon—cleft lip	9.95e-05	0.00119	CbGeAlD
Crizotinib—ABCB1—head—cleft lip	6.2e-05	0.000738	CbGeAlD
Crizotinib—LCK—Adaptive Immune System—FGFR1—cleft lip	6.76e-06	3.33e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FGFR2—cleft lip	6.74e-06	3.32e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—FGFR1—cleft lip	6.7e-06	3.3e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGF8—cleft lip	6.69e-06	3.3e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGF3—cleft lip	6.68e-06	3.29e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—FGF10—cleft lip	6.68e-06	3.29e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—FGFR2—cleft lip	6.68e-06	3.29e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGF3—cleft lip	6.66e-06	3.28e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—FGF10—cleft lip	6.65e-06	3.28e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—FGFR3—cleft lip	6.65e-06	3.28e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—FGF2—cleft lip	6.64e-06	3.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—FGFR2—cleft lip	6.62e-06	3.26e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SPRY2—cleft lip	6.55e-06	3.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF7—cleft lip	6.55e-06	3.23e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—cleft lip	6.52e-06	3.21e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGF9—cleft lip	6.52e-06	3.21e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGF9—cleft lip	6.49e-06	3.2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGF3—cleft lip	6.49e-06	3.2e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTR—cleft lip	6.46e-06	3.18e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGF8—cleft lip	6.45e-06	3.18e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—NOS3—cleft lip	6.43e-06	3.17e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—FGFR3—cleft lip	6.42e-06	3.17e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—FGFR2—cleft lip	6.42e-06	3.16e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—FGFR3—cleft lip	6.38e-06	3.15e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—FGFR1—cleft lip	6.36e-06	3.13e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—FGF2—cleft lip	6.35e-06	3.13e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—FGFR3—cleft lip	6.34e-06	3.12e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—FGF2—cleft lip	6.33e-06	3.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGF9—cleft lip	6.33e-06	3.12e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FGFR1—cleft lip	6.28e-06	3.1e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—FGF2—cleft lip	6.27e-06	3.09e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—NOS3—cleft lip	6.26e-06	3.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FGF10—cleft lip	6.25e-06	3.08e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—FGF2—cleft lip	6.24e-06	3.07e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—FGF2—cleft lip	6.24e-06	3.07e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—FGFR1—cleft lip	6.23e-06	3.07e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—FGF2—cleft lip	6.21e-06	3.06e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—FGFR1—cleft lip	6.17e-06	3.04e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGF3—cleft lip	6.15e-06	3.03e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—NOS3—cleft lip	6.13e-06	3.02e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—FGF2—cleft lip	6.12e-06	3.02e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TCN2—cleft lip	6.12e-06	3.02e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—FGFR2—cleft lip	6.11e-06	3.01e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—FGF2—cleft lip	6.09e-06	3e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—FGF2—cleft lip	6.07e-06	2.99e-05	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—MYC—cleft lip	6.06e-06	2.98e-05	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—MYC—cleft lip	6.06e-06	2.98e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF8—cleft lip	6.04e-06	2.98e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—NOS3—cleft lip	6.04e-06	2.98e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—FGF2—cleft lip	6.02e-06	2.97e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—FGFR3—cleft lip	6.01e-06	2.96e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FGFR2—cleft lip	6.01e-06	2.96e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGF9—cleft lip	6e-06	2.95e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—FGFR1—cleft lip	5.98e-06	2.95e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FGFR3—cleft lip	5.94e-06	2.93e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FGFR2—cleft lip	5.92e-06	2.92e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGF3—cleft lip	5.9e-06	2.91e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—FGFR3—cleft lip	5.89e-06	2.9e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MTHFR—cleft lip	5.89e-06	2.9e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGF10—cleft lip	5.88e-06	2.9e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—FGF2—cleft lip	5.87e-06	2.89e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—FGFR3—cleft lip	5.83e-06	2.87e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTCH1—cleft lip	5.8e-06	2.86e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGF10—cleft lip	5.79e-06	2.86e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FGF10—cleft lip	5.77e-06	2.85e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGF9—cleft lip	5.75e-06	2.83e-05	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—MYC—cleft lip	5.74e-06	2.83e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SPRY2—cleft lip	5.73e-06	2.82e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF7—cleft lip	5.73e-06	2.82e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—FGFR1—cleft lip	5.7e-06	2.81e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FGFR2—cleft lip	5.67e-06	2.79e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—FGFR3—cleft lip	5.65e-06	2.79e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—NOS3—cleft lip	5.63e-06	2.77e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FGFR1—cleft lip	5.6e-06	2.76e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC19A1—cleft lip	5.57e-06	2.75e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FGFR1—cleft lip	5.52e-06	2.72e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FGFR2—cleft lip	5.5e-06	2.71e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGF10—cleft lip	5.5e-06	2.71e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGF10—cleft lip	5.48e-06	2.7e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGF3—cleft lip	5.44e-06	2.68e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTCH1—cleft lip	5.42e-06	2.67e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—FGFR3—cleft lip	5.39e-06	2.65e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—FGFR2—cleft lip	5.36e-06	2.64e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—FGFR2—cleft lip	5.34e-06	2.63e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGF10—cleft lip	5.34e-06	2.63e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGF9—cleft lip	5.31e-06	2.62e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FGFR3—cleft lip	5.29e-06	2.61e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF8—cleft lip	5.29e-06	2.61e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FGFR1—cleft lip	5.28e-06	2.6e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGF3—cleft lip	5.25e-06	2.59e-05	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—MYC—cleft lip	5.25e-06	2.59e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FGFR3—cleft lip	5.22e-06	2.57e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—FGF2—cleft lip	5.15e-06	2.54e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—FGF2—cleft lip	5.14e-06	2.53e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGF9—cleft lip	5.12e-06	2.52e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FGFR1—cleft lip	5.12e-06	2.52e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF7—cleft lip	5.08e-06	2.5e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SPRY2—cleft lip	5.08e-06	2.5e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGF10—cleft lip	5.06e-06	2.49e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FGFR2—cleft lip	5.02e-06	2.47e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—FGFR1—cleft lip	5e-06	2.46e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FGFR3—cleft lip	4.99e-06	2.46e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—NOS3—cleft lip	4.98e-06	2.46e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—FGFR1—cleft lip	4.98e-06	2.45e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—FGF2—cleft lip	4.96e-06	2.45e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—FGF2—cleft lip	4.93e-06	2.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF3—cleft lip	4.92e-06	2.42e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—FGF2—cleft lip	4.9e-06	2.41e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGF10—cleft lip	4.85e-06	2.39e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FGFR3—cleft lip	4.84e-06	2.39e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF9—cleft lip	4.79e-06	2.36e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTCH1—cleft lip	4.75e-06	2.34e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—FGFR3—cleft lip	4.72e-06	2.33e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGFR2—cleft lip	4.72e-06	2.32e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—FGFR3—cleft lip	4.7e-06	2.32e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF8—cleft lip	4.68e-06	2.31e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FGFR1—cleft lip	4.68e-06	2.31e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGFR2—cleft lip	4.65e-06	2.29e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—FGF2—cleft lip	4.64e-06	2.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FGFR2—cleft lip	4.63e-06	2.28e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TCN2—cleft lip	4.62e-06	2.28e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—FGF2—cleft lip	4.59e-06	2.26e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—MYC—cleft lip	4.59e-06	2.26e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—FGF2—cleft lip	4.55e-06	2.24e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NOS3—cleft lip	4.53e-06	2.23e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—FGF2—cleft lip	4.51e-06	2.22e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGF10—cleft lip	4.48e-06	2.21e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MTHFR—cleft lip	4.46e-06	2.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FGFR3—cleft lip	4.42e-06	2.18e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGFR2—cleft lip	4.41e-06	2.17e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGFR2—cleft lip	4.4e-06	2.17e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGFR1—cleft lip	4.4e-06	2.17e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—FGF2—cleft lip	4.37e-06	2.15e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGFR1—cleft lip	4.33e-06	2.14e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGF10—cleft lip	4.32e-06	2.13e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FGFR1—cleft lip	4.32e-06	2.13e-05	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—MYC—cleft lip	4.31e-06	2.12e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF3—cleft lip	4.31e-06	2.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGFR2—cleft lip	4.28e-06	2.11e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—cleft lip	4.26e-06	2.1e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTR—cleft lip	4.24e-06	2.09e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTCH1—cleft lip	4.21e-06	2.07e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF9—cleft lip	4.2e-06	2.07e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—FGF2—cleft lip	4.16e-06	2.05e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGFR3—cleft lip	4.15e-06	2.05e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—MYC—cleft lip	4.15e-06	2.04e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGFR1—cleft lip	4.11e-06	2.03e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NOS3—cleft lip	4.11e-06	2.02e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGFR1—cleft lip	4.1e-06	2.02e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGFR3—cleft lip	4.1e-06	2.02e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—FGF2—cleft lip	4.09e-06	2.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FGFR3—cleft lip	4.08e-06	2.01e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—MYC—cleft lip	4.06e-06	2e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGFR2—cleft lip	4.06e-06	2e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF10—cleft lip	4.04e-06	1.99e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NOS3—cleft lip	4.03e-06	1.99e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—FGF2—cleft lip	4.03e-06	1.99e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—MYC—cleft lip	4e-06	1.97e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGFR1—cleft lip	3.99e-06	1.97e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NOS3—cleft lip	3.98e-06	1.96e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—MTHFR—cleft lip	3.91e-06	1.93e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGFR2—cleft lip	3.89e-06	1.92e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGFR3—cleft lip	3.89e-06	1.91e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGFR3—cleft lip	3.87e-06	1.91e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—FGF2—cleft lip	3.86e-06	1.9e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF3—cleft lip	3.81e-06	1.88e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NOS3—cleft lip	3.81e-06	1.88e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGFR1—cleft lip	3.78e-06	1.86e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGFR3—cleft lip	3.77e-06	1.86e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—FGF2—cleft lip	3.74e-06	1.84e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF9—cleft lip	3.72e-06	1.83e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NOS3—cleft lip	3.69e-06	1.82e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—FGF2—cleft lip	3.65e-06	1.8e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—FGF2—cleft lip	3.63e-06	1.79e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGFR1—cleft lip	3.63e-06	1.79e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGFR2—cleft lip	3.59e-06	1.77e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGFR3—cleft lip	3.58e-06	1.76e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF10—cleft lip	3.54e-06	1.75e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGFR2—cleft lip	3.47e-06	1.71e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—MTHFR—cleft lip	3.46e-06	1.7e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC19A1—cleft lip	3.43e-06	1.69e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGFR3—cleft lip	3.43e-06	1.69e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—FGF2—cleft lip	3.42e-06	1.68e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGFR1—cleft lip	3.35e-06	1.65e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGFR2—cleft lip	3.25e-06	1.6e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGFR1—cleft lip	3.23e-06	1.59e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—FGF2—cleft lip	3.21e-06	1.58e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTR—cleft lip	3.2e-06	1.58e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NOS3—cleft lip	3.17e-06	1.56e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—FGF2—cleft lip	3.17e-06	1.56e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGFR3—cleft lip	3.17e-06	1.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—FGF2—cleft lip	3.15e-06	1.55e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF10—cleft lip	3.14e-06	1.54e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NOS3—cleft lip	3.12e-06	1.54e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS3—cleft lip	3.11e-06	1.53e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGFR3—cleft lip	3.05e-06	1.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGFR1—cleft lip	3.02e-06	1.49e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGF2—cleft lip	3e-06	1.48e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—MYC—cleft lip	3e-06	1.48e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGF2—cleft lip	2.99e-06	1.47e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NOS3—cleft lip	2.96e-06	1.46e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGF2—cleft lip	2.91e-06	1.44e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NOS3—cleft lip	2.87e-06	1.42e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGFR3—cleft lip	2.86e-06	1.41e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TCN2—cleft lip	2.84e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGFR2—cleft lip	2.84e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—FGF2—cleft lip	2.76e-06	1.36e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS3—cleft lip	2.72e-06	1.34e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—MYC—cleft lip	2.72e-06	1.34e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—MYC—cleft lip	2.67e-06	1.32e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGF2—cleft lip	2.65e-06	1.31e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGFR1—cleft lip	2.65e-06	1.31e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—MYC—cleft lip	2.64e-06	1.3e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—TYMS—cleft lip	2.6e-06	1.28e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—MYC—cleft lip	2.52e-06	1.24e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR2—cleft lip	2.52e-06	1.24e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGFR3—cleft lip	2.5e-06	1.23e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—FGF2—cleft lip	2.45e-06	1.21e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MYC—cleft lip	2.45e-06	1.21e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS3—cleft lip	2.41e-06	1.19e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGF2—cleft lip	2.36e-06	1.16e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR1—cleft lip	2.35e-06	1.16e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NOS3—cleft lip	2.33e-06	1.15e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MTHFR—cleft lip	2.27e-06	1.12e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGFR3—cleft lip	2.22e-06	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF2—cleft lip	2.21e-06	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NOS3—cleft lip	2.18e-06	1.07e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—cleft lip	2.1e-06	1.03e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—cleft lip	2.07e-06	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—cleft lip	2.06e-06	1.02e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTR—cleft lip	1.97e-06	9.72e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—cleft lip	1.96e-06	9.67e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TYMS—cleft lip	1.96e-06	9.67e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF2—cleft lip	1.93e-06	9.53e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NOS3—cleft lip	1.91e-06	9.4e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—cleft lip	1.91e-06	9.39e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—cleft lip	1.81e-06	8.9e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MTHFR—cleft lip	1.71e-06	8.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF2—cleft lip	1.71e-06	8.44e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOS3—cleft lip	1.69e-06	8.32e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—cleft lip	1.6e-06	7.88e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—NOS3—cleft lip	1.58e-06	7.8e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—cleft lip	1.54e-06	7.6e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—cleft lip	1.44e-06	7.12e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—cleft lip	1.26e-06	6.23e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TYMS—cleft lip	1.21e-06	5.96e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NOS3—cleft lip	1.2e-06	5.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—cleft lip	1.12e-06	5.52e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MTHFR—cleft lip	1.06e-06	5.2e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NOS3—cleft lip	7.36e-07	3.63e-06	CbGpPWpGaD
